论文部分内容阅读
目的 研究生长抑素 (SS)、血管活性肠肽 (VIP)与心钠素 (ANP)在门脉高压症发病中的作用。 方法 应用放射免疫学方法对 30例门脉高压症患者、30例正常对照者血浆及 2 0份门脉高压性腹水进行 SS、VIP与ANP的检测。 结果 门脉高压症组血浆 SS、VIP与 ANP水平分别为 6 1.2 3± 2 3.85 ,17.6 5± 4.75及 2 0 2 .95±35 .82 pg/ ml,正常对照组分别为 81.2 3± 41.89,13.33± 3.2 9及 97.95± 36 .5 7pg/ ml,二者差别有显著性 (P <0 .0 5 ) ,腹水组分别为 16 4.0 3± 5 8.41,14.92± 3.78及 12 5 .43± 5 0 .0 4pg/ ml,腹水 SS、ANP高于对照组血浆含量(P<0 .0 5 ) ,腹水 VIP与对照组血浆含量差异无显著性。门脉高压症伴腹水者血浆 SS低于无腹水者 ,而 VIP与ANP水平高于无腹水者 (P<0 .0 5 )。 结论 血浆 SS、VIP与 ANP在肝硬化门脉高压症的病理生理机制中起一定作用。
Objective To study the role of somatostatin (SS), vasoactive intestinal peptide (VIP) and atrial natriuretic peptide (ANP) in the pathogenesis of portal hypertension. Methods Radioimmunoassay was used to detect the levels of SS, VIP and ANP in 30 patients with portal hypertension, 30 normal controls and 20 patients with portal hypertension ascites. Results The levels of plasma SS, VIP and ANP in patients with portal hypertension were 6 1.2 3 ± 2 3.85, 17.6 5 ± 4.75 and 2 0 2 .95 ± 35 .82 pg / ml, respectively, and those in the normal control group were 81.2 3 ± 41.89, 13.33 ± 3.2 9 and 97.95 ± 36.57 pg / ml respectively, there was significant difference between the two groups (P <0.05), ascites group were 16 4.03 ± 5 8.41, 14.92 ± 3.78 and 125.53 ± 5 0. 04pg / ml, ascites SS, ANP higher than the control group plasma levels (P <0. 05), ascites VIP and the control group plasma content was no significant difference. Patients with portal hypertension had lower serum SS than those without ascites, while those with VIP and ANP were higher than those without ascites (P <0.05). Conclusions Plasma SS, VIP and ANP play a role in the pathophysiological mechanism of cirrhosis and portal hypertension.